Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Public ClinicalTrials.gov record NCT01606241. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer
Study identification
- NCT ID
- NCT01606241
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 24 participants
Conditions and interventions
Conditions
- Recurrent Breast Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Stage IIA Breast Cancer
- Stage IIA Fallopian Tube Cancer
- Stage IIA Ovarian Cancer
- Stage IIB Breast Cancer
- Stage IIB Fallopian Tube Cancer
- Stage IIB Ovarian Cancer
- Stage IIC Fallopian Tube Cancer
- Stage IIC Ovarian Cancer
- Stage IIIA Breast Cancer
- Stage IIIA Fallopian Tube Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Primary Peritoneal Cancer
- Stage IIIB Breast Cancer
- Stage IIIB Fallopian Tube Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Primary Peritoneal Cancer
- Stage IIIC Breast Cancer
- Stage IIIC Fallopian Tube Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Primary Peritoneal Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Cancer
- Stage IV Primary Peritoneal Cancer
Interventions
- Cyclophosphamide Drug
- Laboratory Biomarker Analysis Other
- Multi-epitope Folate Receptor Alpha Peptide Vaccine Biological
Drug · Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 23, 2012
- Primary completion
- Sep 24, 2014
- Completion
- Mar 8, 2018
- Last update posted
- Aug 20, 2024
2012 – 2018
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01606241, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2024 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01606241 live on ClinicalTrials.gov.